Skip to main content

Advertisement

SpringerLink
Log in

Valproate-induced hyperammonaemia superimposed upon severe neuropsychiatric lupus: a case report and review of the literature

  • Case Based Review
  • Published:
Clinical Rheumatology Aims and scope Submit manuscript

Abstract

This paper presents a case of systemic lupus erythematosus (SLE) with neuropsychiatric features, where the outcome was influenced by the development of hyperammonaemia, probably induced by sodium valproate. A case of severe SLE occurring in a 20-year-old Maori girl is described. Her disease had been characterised by neuropsychiatric features for several years, culminating in persistent seizure activity at the time of her final presentation. Her management with anticonvulsants was complicated by the development of intractable hyperammonaemia which contributed to irreversible clinical deterioration. We have reviewed the English literature for reports of valproate-related hyperammonaemia which has often been described in the setting of seizure and mood disorders. This is the first case where it has been reported, superimposed upon severe neuropsychiatric SLE (NP-SLE). The mechanism by which valproate induces hyperammonaemia remains incompletely understood but is likely to relate to the urea cycle. Under normal metabolic conditions, acyl-CoA is transported into the mitochondria via a carnitine transport system. It is then converted to acetyl-CoA via β-oxidation and eventually to N-acetyl glutamate. This pathway can be interrupted by the introduction of sodium valproate, leading to a reduction of free coenzyme A, acetyl-CoA and carnitine, and resulting in the decreased availability of cofactors necessary for the function of the urea cycle. As this is the primary means of ammonia metabolism, serious elevation in serum ammonia levels may occur in patients on this anticonvulsant medication. In this patient with active NP-SLE, the combined autoimmune and metabolic brain insult contributed to a fatal outcome.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Fig. 1

Similar content being viewed by others

References

  1. Churg J, Sobin LH (1982) Renal diseases: classification and atlas of glomerular disease. Igaku-Shoin, Tokyo

    Google Scholar 

  2. American College of Rheumatology (ACR) (1999) The American College of Rheumatology nomenclature and case definitions for neuropsychiatric lupus syndrome. Arthritis Rheum 42(4):599–608

    Article  Google Scholar 

  3. Hanly JG, Walsh NM, Sangalang V (1992) Brain pathology in systemic lupus erythematosus. J Rheumatol 19(5):732–741

    PubMed  CAS  Google Scholar 

  4. Sterling G, West MD (1996) Lupus and the central nervous system. Curr Opin Rheumtol 8:408–414

    Article  Google Scholar 

  5. Hanly JG, Harrison MJ (2005) Management of neuropsychiatric lupus. Best Pract Res Clin Rheumatol 19(5):799–821

    Article  PubMed  Google Scholar 

  6. Sanna G, Bertolaccini ML, Cuadrado MJ et al (2005) Neuropsychiatric manifestations in systemic lupus erythematosus: prevalence and association with antiphospholipid antibodies. J Rheumatol 30(5):985–992

    Google Scholar 

  7. DeGiorgio LA, Konstantinov KN, Lee SC, Hardin JA, Volpe BT, Diamond B (2001) A subset of lupus anti-DNA antibodies cross-reacts with the NR2 glutamate receptor in systemic lupus erythematosus. Nat Med 7:1189–1193

    Article  PubMed  CAS  Google Scholar 

  8. Campostrini R, Zaccara G, Rossi L, Paganini M, Dorigotti A, Zappoli R (1985) Valproate-induced hyperammonaemia in two epileptic identical twins. J Neurol 232:167–168

    Article  PubMed  CAS  Google Scholar 

  9. Kulick SK, Kramer DA (1993) Hyperammonemia secondary to valproic acid as a cause of lethargy in a postictal patient. Ann Emerg Med 22:610–612

    Article  PubMed  CAS  Google Scholar 

  10. Oechsner M, Steen C, Sturenburg HJ, Kohlschutter A (1998) Hyperammonaemic encephalopathy after initiation of valproate therapy in unrecognized ornithine transcarbamylase deficiency. J Neurol Neurosurg Psychiatry 64:680–682

    Article  PubMed  CAS  Google Scholar 

  11. Blindauer KA, Harrington G, Morris GL, Ho K (1998) Fulminant progression of demyelinating disease after valproate-induced encephalopathy. Neurology 51:292–295

    Article  PubMed  CAS  Google Scholar 

  12. Vossler DG, Wilensky AJ, Cawthon DF et al (2002) Serum and CSF glutamine levels in valproate-related hyperammonemic encephalopathy. Epilepsi 43(2):154–159

    Article  CAS  Google Scholar 

  13. Ziyeh S, Thiel T, Spreer J, Klisch J, Schumacher M (2002) Valproate-induced encephalopathy: assessment with MR imaging and 1H MR spectroscopy. Epilepsia 43(9):1101–1105

    Article  PubMed  Google Scholar 

  14. Feil D, Chuang K, Sultzer DL (2002) Valproate-induced hyperammonemia as a cause of altered mental status. Am J Geriatr Psychiatr 10(4):476–478

    Google Scholar 

  15. O’Neill M, Dubrey RW, Grocott-Mason RM (2002) Valproate encephalopathy and hyperammonaemia. Postgrad Med J 78:316–318

    Article  PubMed  Google Scholar 

  16. Lokrantz CM, Eriksson B, Rosen I, Asztely F (2004) Hyperammonemic encephalopathy induced by a combination of valproate and pivmecillinam. Acta Neurol Scand 109:297–301

    Article  PubMed  Google Scholar 

  17. Mallet L, Babin S, Morais JA (2004) Valproic acid-induced hyperammonemia and thrombocytopenia in an elderly woman. Ann Pharmacother 38:1643–1647

    Article  PubMed  Google Scholar 

  18. Latour P, Biraben A, Polard E et al (2004) Drug induced encephalopathy in six epileptic patients: topiramate? valproate? or both? Hum Psychopharmacol Clin Exp 19:193–203

    Article  CAS  Google Scholar 

  19. Cuturic M, Abramson RK (2005) Acute hyperammonemic coma with chronic valproic acid therapy. Ann Pharmacother 39:2119–2123

    Article  PubMed  Google Scholar 

  20. Soares-Fernandes JP, Machado A, Ribeiro M, Ferreira C, Figueiredo J, Rocha JF (2006) Hippocampal involvement in valproate-induced acute hyperammonemic encephalopathy. Arch Neurol 63:1202–1203

    Article  PubMed  Google Scholar 

  21. Pradeep R (2008) Valproate monotherapy induced-delirium due to hyperammonemia: a report of three adult cases with different types of presentation. Indian J Psychiatr 50(2):121–123

    Article  Google Scholar 

  22. Gerstner T, Buesing D, Longin E et al (2006) Valproic acid induced encephalopathy—19 new cases in Germany from 1994 to 2003—a side effect associated to VPA-therapy not only in young children. Seizure 15:443–448

    Article  PubMed  Google Scholar 

  23. Gomceli YB, Kutlu G, Cavdar L, Sanivar F, Inan LE (2007) Different clinical manifestations of hyperammonemic encephalopathy. Epilepsy Behav 10(4):583–587

    Article  PubMed  CAS  Google Scholar 

  24. Chan YC, Tse ML, Lau FL (2007) Two cases of valproic acid poisoning treated with l-carnitine. Hum Exp Toxicol 26:967–969

    Article  PubMed  CAS  Google Scholar 

  25. McCall M, Bourgeois JA (2004) Valproic acid induced hyperammonaemia: a case report. J Clin Psychopharmacol 24(5):521–526

    Article  PubMed  Google Scholar 

  26. Davison AS, Milan AM, Roberts NB (2011) The consequences of valproate overdose. Clin Chem 57(9):1223–1238

    Article  Google Scholar 

  27. Gomez-Ibanez A, Urrestarazu-Bolumburu E, Viteri-Torres C (2011) Hyperammonemic encephalopathy related to valproate, phenobarbital, and topiramate synergism. Epilepsy Behav 21(4):480–482

    Article  PubMed  Google Scholar 

  28. Prins MC, van Meijel JJ (2011) A case of hyperammonaemic encephalopathy due to valproic acid. Neth J Med 69(9):389–391

    PubMed  CAS  Google Scholar 

  29. LaBuzetta JN, Yao JZ, Bourque DL, Zivin J (2010) Adult nonhepatic hyperammonemia: a case report and differential diagnosis. Am J Med 123(10):885–891

    Article  PubMed  Google Scholar 

  30. Eze E, Workman M, Donley B (1998) Hyperammonemia and coma developed by a woman treated with valproic acid for affective disorder. Psychiatr Serv 49:1358–1359

    PubMed  CAS  Google Scholar 

  31. Barrueto F, Hack JB (2001) Hyperammonemia and coma without hepatic dysfunction induced by valproate therapy. Acad Emerg Med 8:999–1001

    Article  PubMed  Google Scholar 

  32. Stewart J (2008) A case of hyperammonemic encephalopathy after 11 years of valproate therapy. J Clin Psychopharmcol 28(3):361–362

    Article  Google Scholar 

  33. Wadzinski J, Franks R, Roane D, Bayard M (2007) Valproate-associated hyperammonemic encephalopathy. J Am Board Fam Med 20:499–502

    Article  PubMed  Google Scholar 

  34. Raby WN (1997) Carnitine for valproic acid-induced hyperammonemia. Am J Psychiatry 154(8):1168–1169

    PubMed  CAS  Google Scholar 

  35. Panikkar GP, Gilman SM (1999) Valproate-induced hyperammonemia in the psychiatric setting: 2 cases. J Clin Psychiatry 60:557–559

    Article  PubMed  CAS  Google Scholar 

  36. Elgudin L, Hall Y, Schubert D (2003) Ammonia induced encephalopathy from valproic acid in a bipolar patient: case report. Int J Psychiatry Med 33:91–96

    Article  PubMed  Google Scholar 

  37. Eubanks AL, Aguirre B, Bourgeois JA (2008) Severe acute hyperammonemia after brief exposure to valproate. Psychosomatics 49:82–83

    Article  PubMed  Google Scholar 

  38. Abreu LN, Issler C, Lafer B (2009) Valproate-induced reversible pseudoatrophy of the brain and hyperammonemic encephalopathy in a bipolar patient. Aust N Z J Psychiatr 43:484–485

    Article  Google Scholar 

  39. Shan JC, Hsieh MH, Liu CC, Wen CC, Liu CM (2010) Clinical alertness to valproic acid-induced hyperammonemia—two case reports. J Psychopharmacol 24(6):943–945

    Article  PubMed  CAS  Google Scholar 

  40. Rupasinghe J, Jasinarachchi M (2011) Progressive encephalopathy with cerebral oedema and infarctions associated with valproate and diazepam overdose. J Clin Neurosci 18(5):710–711

    Article  PubMed  CAS  Google Scholar 

  41. Settle EC Jr (1995) Valproic acid-associated encephalopathy with coma. Am J Psychiatry 152(8):1236–1237

    PubMed  Google Scholar 

  42. Kimmel RJ, Irwin SA, Meyer JM (2005) Valproic acid-associated hyperammonemic encephalopathy: a case report from the psychiatric setting. Int Clin Psychopharmacol 20:57–58

    Article  PubMed  Google Scholar 

  43. Carr RB, Shrewsbury K (2007) Hyperammonemia due to valproic acid in the psychiatric setting. Am J Psychiatry 164(7):1020–1027

    Article  PubMed  Google Scholar 

  44. Hung CC, Li TM, Wei IH, Huang CC (2011) The real mechanism of VPA-induced hyperammonemia remains unknown. Gen Hosp Psychiatr 33(1):84, e3-4

    Article  Google Scholar 

  45. Reif A, Leonhard C, Mobner R, Lesch KP, Fallgatter AJ (2004) Encephalopathy and myoclonus triggered by valproic acid. Prog Neuropsychopharmacol Biol Psychiatr 28:1061–1063

    Article  CAS  Google Scholar 

  46. Stewart JT (2005) Treatment of valproate-induced hyperammonemia. J Am Geriatr Soc 53:1080

    Article  PubMed  Google Scholar 

  47. Khoo CL, Naik S, Lua R, Chai SB, Liew A, Sim K (2010) Valproate-induced hyperammonemia in mental retardation: a case report and review of the literature. Prog Neuropsychpharmacol Biol Psychiatr 34:561–562

    Article  Google Scholar 

  48. Starer J, Chang G (2010) Hyperammoneic encephalopathy, valproic acid, and benzodiazepine withdrawal: a case series. Am J Drug Alcohol Abuse 36:98–101

    Article  PubMed  Google Scholar 

  49. Mittal V, Muralee S, Tampi RR (2009) Valproic acid-induced hyperammonemia in the elderly: a review of the literature. Case Report Med 2009:802121

    Google Scholar 

  50. Ott CA, Campbell N, Dworek EA (2007) Valproic acid-induced hyperammonaemia in a patient with schizoaffective disorder. J Pharm Prac 20(1):82–92

    Article  Google Scholar 

Download references

Disclosures

None.

Author information

Authors and Affiliations

  1. Department of Rheumatology, Greenlane Clinical Centre, Auckland District Health Board, Private Bag 92024, Auckland Mail Centre, Auckland, 1142, New Zealand

    Estee Chan & Fiona McQueen

  2. Department of Molecular Medicine and Pathology, University of Auckland, Auckland, New Zealand

    Fiona McQueen

Authors
  1. Estee Chan
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Fiona McQueen
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Estee Chan.

Electronic supplementary material

Below is the link to the electronic supplementary material.

ESM 1

(DOCX 29.6 kb)

Rights and permissions

Reprints and permissions

About this article

Cite this article

Chan, E., McQueen, F. Valproate-induced hyperammonaemia superimposed upon severe neuropsychiatric lupus: a case report and review of the literature. Clin Rheumatol 32, 403–407 (2013). https://doi.org/10.1007/s10067-012-2150-x

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s10067-012-2150-x

Keywords

Search

Navigation